Pharsight

Qulipta generic

Qulipta is an anti-migraine drug owned by Abbvie Inc. The active ingredient in Qulipta is atogepant. The drug received its first market authorization on 28 September, 2021, and is available in tablet form for oral administration. Qulipta holds a total of 4 patents, none of which have expired.

When will Qulipta generic be available?

The Qulipta generic is projected to be available after 30 January, 2035. This is determined by its patent status. Although patent challenges can be filed against Qulipta from 2025-09-28, the most pertinent patent 'Tablet formulation for CGRP active compounds' (US10117836) is due to expire on 2035-01-30, which will lead to the availability of the generic version.

Qulipta uses

Qulipta is predominantly used for the preventive treatment of episodic migraine in adults. The active ingredient, atogepant, contributes to its effectiveness by blocking the CGRP receptor, which is associated with migraines.

Qulipta patent expiration

Qulipta holds 4 active patents with the latest one ending in 2035. The 'Tablet formulation for CGRP active compounds' (US10117836) is the most influential, impacting the release of the Qulipta generic. Below are the details of the patent:

Qulipta dosage

Want to ask something?